Form 4: Alnylam Pharmaceuticals Executive Receives Significant Equity Grant and 401(k) Shares

Alnylam Pharmaceuticals' Chief Scientific Officer and EVP, Head of Research, Kevin Joseph Fitzgerald, was granted 7,763 restricted stock units, vesting over three years, and acquired additional shares through the company's 401(k) matching program.

Summary

• Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, Inc. (ALNY), was granted 7,763 restricted stock units (RSUs) on July 1, 2025.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date, contingent on continuous service.
• Fitzgerald also acquired 537 shares of ALNY common stock indirectly through a managed account, specifically via the issuer's 401(k) matching contribution program.
• Following these transactions, Fitzgerald beneficially owns 21,264 shares directly and 537 shares indirectly.

Sentiment

Score: 7

Explanation: The document reports a standard executive equity grant and 401(k) share acquisition, which are positive for executive alignment and retention but do not indicate significant new operational or financial developments.

Positives

• The grant of 7,763 restricted stock units aligns the executive's incentives with long-term shareholder value creation.
• The acquisition of shares through the 401(k) matching program indicates continued participation in employee benefit plans.

Negatives

• No immediate negative financial implications or sales of shares were reported.

Future Outlook

The granted restricted stock units are set to vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the July 1, 2025 grant date, contingent on the reporting person's continuous service.

Industry Context

This filing is a routine disclosure of executive compensation in the form of equity grants, common practice in the biotechnology and pharmaceutical industry to incentivize long-term executive retention and performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with multi-year vesting is a standard practice for executive compensation across the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance.
• The provision of a 401(k) matching contribution program is also a common employee benefit, comparable to those offered by other major pharmaceutical companies like Pfizer, Moderna, or Johnson & Johnson, aimed at employee retention and financial well-being.

Related Party Transactions

• The grant of Restricted Stock Units to an executive is a form of related party transaction, as it involves compensation from the company to a key management personnel.
• The acquisition of shares through the company's 401(k) matching contribution program is also a transaction between the company and a related party (executive).

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with long-term shareholder value. The increase in outstanding shares upon vesting will be minimal.
• Employees: The 401(k) matching program demonstrates a commitment to employee benefits, which can positively impact morale and retention.
• Management: The RSU grant provides a significant incentive for the Chief Scientific Officer to remain with the company and contribute to its long-term success.

Next Steps

• One-third of the granted RSUs will vest on July 1, 2026, subject to continuous service.
• One-third of the granted RSUs will vest on July 1, 2027, subject to continuous service.
• One-third of the granted RSUs will vest on July 1, 2028, subject to continuous service.

Key Dates

Recommendation

Keywords

Alnylam Pharmaceuticals, ALNY, Restricted Stock Units, RSU, Insider Trading, SEC Form 4, Executive Compensation, Stock Grant, Employee Stock Plan, 401k